First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

2011542 citationsJournal Article

Authors

Timothy A. Yap

Yan Li · Merck (Japan)

Amita Patnaik · South Texas Accelerated Research Therapeutics

Ivy Fearen · Merck (Japan)

David Olmos · Royal Marsden NHS Foundation Trust

Kyriakos P. Papadopoulos · South Texas Accelerated Research Therapeutics

Richard D. Baird

Liliana Delgado

Abstract

MK-2206 was well tolerated, with evidence of AKT signaling blockade. Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Biochemical and Molecular Research Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 35, pp. 4688-4695

DOI: 10.1200/jco.2011.35.5263

Field-Weighted Citation Impact: 22.41